Abstract
The management of chronic hand eczema is challenging and includes several behavioral and medical measures. A subset of patient will not respond to topical treatment strategies alone, but may benefit from systemic therapy. In this chapter, selected immunomodulating drugs (azathioprin, cyclosporine, methotrexate) which have been successfully used for the systemic treatment of chronic hand eczema is reviewed regarding their clinical pharmacology, mechanisms of action, efficacy, and safety.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Anstey AV, Wakelin S, Reynolds NJ (2004) British Association of Dermatologists Therapy G, Audit S. Guidelines for prescribing azathioprine in dermatology. Br J Dermatol 151(6):1123–1132
Granlund H, Erkko P, Eriksson E, Reitamo S (1996) Comparison of cyclosporine and topical betamethasone-17, 21-dipropionate in the treatment of severe chronic hand eczema. Acta Derm Venereol 76(5):371–376
Griffiths CE, Katsambas A, Dijkmans BA et al (2006) Update on the use of ciclosporin in immune-mediated dermatoses. Br J Dermatol 155(Suppl 2):1–16
Levy LL, Urban J, King BA (2015) Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol 73(3):395–399
Longo-Sorbello GS, Bertino JR (2001) Current understanding of methotrexate pharmacology and efficacy in acute leukemias. Use of newer antifolates in clinical trials. Haematologica 86(2):121–127
Lyakhovitsky A, Barzilai A, Heyman R et al (2010) Low-dose methotrexate treatment for moderate-to-severe atopic dermatitis in adults. J Eur Acad Dermatol Venereol 24(1):43–49
Morabito L, Montesinos MC, Schreibman DM et al (1998) Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5′-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest 101(2):295–300
Mrowietz U, Klein CE, Reich K et al (2009) Cyclosporine therapy in dermatology. J Dtsch Dermatol Ges 7(5):474–479
Sahasranaman S, Howard D, Roy S (2008) Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol 64(8):753–767
Simpson EL, Bieber T, Guttman-Yassky E et al (2016) Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 375(24):2335–2348
Thomas CW, Myhre GM, Tschumper R et al (2005) Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. J Pharmacol Exp Ther 312(2):537–545
Verma KK, Bansal A, Sethuraman G (2006) Parthenium dermatitis treated with azathioprine weekly pulse doses. Indian J Dermatol Venereol Leprol 72(1):24–27
Verma KK, Mahesh R, Srivastava P, Ramam M, Mukhopadhyaya AK (2008) Azathioprine versus betamethasone for the treatment of parthenium dermatitis: a randomized controlled study. Indian J Dermatol Venereol Leprol 74(5):453–457
Weatherhead SC, Wahie S, Reynolds NJ, Meggitt SJ (2007) An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. Br J Dermatol 156(2):346–351
Wise M, Callen JP (2007) Azathioprine: a guide for the management of dermatology patients. Dermatol Ther 20(4):206–215
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this entry
Cite this entry
da Mota, R., Homey, B. (2020). Treatment of Chronic Hand Eczema: Other Immunomodulating Therapies. In: John, S., Johansen, J., Rustemeyer, T., Elsner, P., Maibach, H. (eds) Kanerva’s Occupational Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-319-68617-2_93
Download citation
DOI: https://doi.org/10.1007/978-3-319-68617-2_93
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-68615-8
Online ISBN: 978-3-319-68617-2
eBook Packages: MedicineReference Module Medicine